1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
  4. > Leishmaniasis (Kala-Azar)-Pipeline Insights, 2014

SUMMARY
DelveInsight’s,“ Leishmaniasis (Kala-Azar)-Pipeline Insights, 2014”, report provides comprehensive insights about pipeline drugs across this indication. A key objective of the report is to establish the understanding for all the pipeline drugs that fall under Leishmaniasis (Kala-Azar). This report provides information on the therapeutic development based on the Leishmaniasis (Kala-Azar) dealing with all the pipeline drugs, comparative analysis at various stages covering Filed, Phase III, Phase II, Phase I, IND filed, Preclinical, Discovery and unknown stages, therapeutics assessment by monotherapy and combination products and molecule type drug information. The report also covers the companies information involved in the therapeutic development of the products. It also has highlighted the discontinued and dormant products.
Data Sources

The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by DelveInsight team of industry experts.

Secondary sources information and data has been collected from various printable and non-printable sources like search engines, News websites, Government Websites, Trade Journals, White papers, Magazines, Trade associations, Books, Industry Portals, Industry Associations and access to available databases.

Note*: This report requires certain updates. We have all the information available but require 3 business days to complete the process and ensure it is as up-to-date as possible. Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated Indication.

Scope
- The report provides a snapshot of the global therapeutic landscape of Leishmaniasis (Kala-Azar)
- The report provides pipeline products under drug profile section which includes product description, MOA, licensors & collaborators, development partner and chemical information
- Coverage of the Leishmaniasis (Kala-Azar) pipeline on the basis of target, MOA, route of administration, technology involved and molecule type
- The report reviews key players involved in the therapeutics development for Leishmaniasis (Kala-Azar) and also provide company profiling
- The report also gives the information of dormant and discontinued pipeline projects
- Pipeline products coverage based on various stages of development ranging from preregistration till discovery and undisclosed stages
- Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type


Reasons to buy
- Complete Pipeline intelligence and complete understanding over therapeutics development for Leishmaniasis (Kala-Azar)
- Identify the relationship between the drugs and use it for target finding, drug repurposing, and precision medicine.
- Devise corrective measures for pipeline projects by understanding Leishmaniasis (Kala-Azar) pipeline depth and focus of Indication therapeutics
- Developing strategic initiatives to support your drug development activities.
- Optimize your portfolio and keep you in touch with the rapidly changing pharmaceutical markets, and make the best decisions for your business.
- Develop and design in licensing and out licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
- Gaining a Full Picture of the Competitive Landscape for Evidence based Decisions

Table Of Contents

Leishmaniasis (Kala-Azar)-Pipeline Insights, 2014
Table of Contents
- Leishmaniasis (Kala-Azar) Overview
- Leishmaniasis (Kala-Azar) Pipeline Therapeutics
- Leishmaniasis (Kala-Azar) Therapeutics under Development by Companies
- Leishmaniasis (Kala-Azar) Late Stage Products (Filed and Phase III)
- Comparative Analysis
- Leishmaniasis (Kala-Azar) Mid Clinical Stage Products (Phase II)
- Comparative Analysis
- Leishmaniasis (Kala-Azar) Early Clinical Stage Products (Phase I and IND Filed)
- Comparative Analysis
- Leishmaniasis (Kala-Azar) Discovery and Pre-Clinical Stage Products
- Comparative Analysis
- Drug Candidate Profiles
- Leishmaniasis (Kala-Azar) - Therapeutics Assessment
- Assessment by Monotherapy Products
- Assessment by Combination Products
- Assessment by Route of Administration
- Assessment by Molecule Type
- Leishmaniasis (Kala-Azar) - Discontinued Products
- Leishmaniasis (Kala-Azar) - Dormant Products
- Companies Involved in Therapeutics Development for Leishmaniasis (Kala-Azar)
- Appendix
- Methodology
- Contact Us
- Disclaimer

List of Tables

- Number of Products under Development for Leishmaniasis (Kala-Azar), 2014
- Number of Products under Development by Companies
- Comparative Analysis by Late Clinical Stage Products (Filed and Phase III), 2014
- Comparative Analysis Mid Clinical Stage Products (Phase II), 2014
- Comparative Analysis Early Clinical Stage Products (Phase I and IND Filed), 2014
- Comparative Analysis Discovery and Pre-Clinical Stage Products, 2014
- Drug Candidates Profiles
- Leishmaniasis (Kala-Azar) Assessment by Monotherapy Products
- Leishmaniasis (Kala-Azar) Assessment by Combination Products
- Leishmaniasis (Kala-Azar) Assessment by Route of Administration
- Leishmaniasis (Kala-Azar) Assessment by Stage and Route of Administration
- Leishmaniasis (Kala-Azar) Assessment by Molecule Type
- Leishmaniasis (Kala-Azar) Assessment by Stage and Molecule Type
- Leishmaniasis (Kala-Azar) Therapeutics - Discontinued Products
- Leishmaniasis (Kala-Azar) Therapeutics - Dormant Products
- Products under Development by Companies, 2014

List of Figures

- Number of Products under Development for Leishmaniasis (Kala-Azar), 2014
- Late Clinical Stage Products (Filed and Phase III), 2014
- Mid Clinical Stage Products (Phase II), 2014
- Early Clinical Stage Products (Phase I and IND Filed), 2014
- Discovery and Pre-Clinical Stage Products, 2014
- Leishmaniasis (Kala-Azar) Assessment by Monotherapy Products
- Leishmaniasis (Kala-Azar) Assessment by Combination Products
- Leishmaniasis (Kala-Azar) Assessment by Route of Administration
- Leishmaniasis (Kala-Azar) Assessment by Stage and Route of Administration
- Leishmaniasis (Kala-Azar) Assessment by Molecule Type
- Leishmaniasis (Kala-Azar) Assessment by Stage and Molecule Type

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
World Infectious Disease Testing Market Future Horizons and Growth Strategies: Supplier Shares by Test, Country Segment Forecasts, Competitive Intelligence, Opportunities

World Infectious Disease Testing Market Future Horizons and Growth Strategies: Supplier Shares by Test, Country Segment Forecasts, Competitive Intelligence, Opportunities

  • $ 21 100
  • Industry report
  • August 2016
  • by Venture Planning Group

Complete report $34,500.  DataPack (test volumes, sales forecasts, supplier shares) $21,100. VPGMarketResearch.com's new report is a seven-country strategic analysis of major business opportunities emerging ...

Infectious Diseases: US, Europe, Japan--Market Analysis, Competitive Intelligence, Technology Trends, Opportunities for Suppliers

Infectious Diseases: US, Europe, Japan--Market Analysis, Competitive Intelligence, Technology Trends, Opportunities for Suppliers

  • $ 21 100
  • Industry report
  • June 2016
  • by Venture Planning Group

This comprehensive seven-country report contains 1,954 pages, 824 tables, and is designed to assist diagnostics industry executives, as well as companies planning to diversify into the dynamic and rapidly ...

Infectious Diseases 2016-2020: Supplier Shares, Competitive Strategies, Country Volume and Sales Segment Forecasts for 100 Tests, Innovative Technologies, Instrumentation Review

Infectious Diseases 2016-2020: Supplier Shares, Competitive Strategies, Country Volume and Sales Segment Forecasts for 100 Tests, Innovative Technologies, Instrumentation Review

  • $ 21 100
  • Industry report
  • May 2016
  • by Venture Planning Group

Complete report $34,500.  DataPack (test volumes, sales forecasts, supplier shares) $21,100. This comprehensive seven-country report contains 1,954 pages, 824 tables, and is designed to assist diagnostics ...


Download Unlimited Documents from Trusted Public Sources

Infectious Disease Statistics in Argentina

  • August 2016
  • Infectious Dise...  

    Asthma  

  • Argentina  

    Taiwan  

    South America  

View report >

Infectious Disease Statistics in South Sudan

  • August 2016
    207 pages
  • Infectious Dise...  

    Food  

  • South Sudan  

    Africa  

    Sudan  

View report >

Infectious Disease Statistics

  • August 2016
    208 pages
  • Infectious Dise...  

    Food  

  • South Sudan  

    Africa  

    Sudan  

View report >

Related Market Segments :

Infectious Disease

ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.